Spots Global Cancer Trial Database for Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Official Title: An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Study ID: NCT00427583
Conditions
Interventions
Study Description
Brief Summary: This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Hamburg, , Germany
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmeceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
